Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178415 | 0.85 | KDM4E (0.65) | NPC1RAB9ACYP2C9CYP2C19MEN1 | |
| SCHEMBL2399070 | 0.84 | POLB (0.61) | NPC1RAB9ACYP2C9CYP2C19MEN1 | |
| SCHEMBL104586 | 0.83 | RAB9A (1.00) | NPC1RAB9ACYP2C9CYP2C19MEN1 | |
| SCHEMBL12693 | 0.82 | ALDH1A1 (0.76) | NPC1RAB9ACYP2C9CYP2C19MEN1 | |
| SCHEMBL19016264 | 0.81 | ALDH1A1 (0.67) | MEN1KMT2ASMN1; SMN2GAANPSR1 | |
| SCHEMBL15033571 | 0.80 | NPC1 (0.70) | NPC1RAB9ACYP2C9CYP2C19MEN1 | |
| SCHEMBL21348459 | 0.80 | NPC1 (0.65) | NPC1RAB9ACYP2C9CYP2C19NPY5R | |
| SCHEMBL1097789 | 0.79 | NPC1 (0.68) | NPC1RAB9ACYP2C9CYP2C19MEN1 | |
| SCHEMBL1407210 | 0.79 | NPC1 (0.68) | NPC1RAB9ACYP2C9CYP2C19MEN1 | |
| SCHEMBL20237020 | 0.79 | SMN1; SMN2 (0.68) | NPC1RAB9ACYP2C9CYP2C19NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | NPC1 1892/4885RAB9A 3030/4885CYP2C9 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.